Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Declines By 25.0%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 79,900 shares, a decline of 25.0% from the September 30th total of 106,500 shares. Based on an average daily volume of 175,500 shares, the days-to-cover ratio is currently 0.5 days. Approximately 6.1% of the shares of the company are sold short.

Sonoma Pharmaceuticals Trading Down 3.3 %

NASDAQ SNOA traded down $0.10 during trading on Tuesday, reaching $2.90. The company’s stock had a trading volume of 22,868 shares, compared to its average volume of 162,725. The firm has a 50 day moving average price of $2.76 and a 200 day moving average price of $1.13. Sonoma Pharmaceuticals has a 12 month low of $2.32 and a 12 month high of $9.37. The firm has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.28 and a beta of 1.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The company had revenue of $3.39 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 35.91% and a negative return on equity of 65.66%. On average, equities analysts forecast that Sonoma Pharmaceuticals will post -4 EPS for the current fiscal year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.